First Horizon Advisors Inc. Has $119,000 Stake in UiPath Inc. (NYSE:PATH)

First Horizon Advisors Inc. lessened its holdings in shares of UiPath Inc. (NYSE:PATH) by 28.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,793 shares of the healthcare company’s stock after selling 1,865 shares during the period. First Horizon Advisors Inc.’s holdings in UiPath were worth $119,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in UiPath by 7.6% during the third quarter. Vanguard Group Inc. now owns 37,750,773 shares of the healthcare company’s stock worth $645,916,000 after buying an additional 2,673,718 shares in the last quarter. FMR LLC grew its stake in shares of UiPath by 2.9% during the third quarter. FMR LLC now owns 16,238,176 shares of the healthcare company’s stock worth $277,835,000 after buying an additional 463,032 shares during the last quarter. Senvest Management LLC increased its holdings in shares of UiPath by 3.0% during the third quarter. Senvest Management LLC now owns 6,209,655 shares of the healthcare company’s stock worth $106,247,000 after buying an additional 181,722 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of UiPath by 2.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301,413 shares of the healthcare company’s stock valued at $131,687,000 after acquiring an additional 119,782 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of UiPath by 10.4% during the 3rd quarter. Northern Trust Corp now owns 2,467,710 shares of the healthcare company’s stock valued at $42,223,000 after acquiring an additional 233,362 shares in the last quarter. 62.50% of the stock is owned by institutional investors.

UiPath Trading Up 1.8 %

Shares of PATH stock opened at $19.84 on Tuesday. UiPath Inc. has a fifty-two week low of $12.89 and a fifty-two week high of $27.87. The stock has a 50 day simple moving average of $21.75 and a two-hundred day simple moving average of $21.72.

UiPath (NYSE:PATH) last released its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.10. The company had revenue of $405.25 million during the quarter, compared to analyst estimates of $383.32 million. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. On average, analysts forecast that UiPath Inc. will post -0.04 earnings per share for the current year.

Insider Activity

In related news, CFO Ashim Gupta sold 40,000 shares of the business’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $21.66, for a total value of $866,400.00. Following the completion of the sale, the chief financial officer now directly owns 660,762 shares of the company’s stock, valued at approximately $14,312,104.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 31.03% of the company’s stock.

Wall Street Analysts Forecast Growth

PATH has been the subject of a number of recent research reports. Truist Financial reaffirmed a “buy” rating and issued a $32.00 target price on shares of UiPath in a report on Wednesday, March 20th. Royal Bank of Canada reiterated a “sector perform” rating and set a $29.00 target price on shares of UiPath in a research report on Monday, April 1st. KeyCorp assumed coverage on shares of UiPath in a report on Monday, April 8th. They set an “overweight” rating and a $27.00 target price on the stock. Canaccord Genuity Group raised their price target on shares of UiPath from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $30.00 price objective on shares of UiPath in a research note on Wednesday, March 20th. Nine equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, UiPath currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.41.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.